HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Basal cell carcinoma — Clinical Guidelines

Overview

Basal cell carcinoma (BCC) is the most common type of skin cancer, predominantly affecting fair-skinned individuals. It is characterized by slow growth and low metastatic potential but can cause significant local tissue destruction if left untreated 1 6 7.

Diagnosis

Clinical examination often sufficient for diagnosis, especially in typical presentations 1 17.

Histopathological confirmation recommended for atypical or clinically uncertain lesions 1 17.

Optical coherence tomography (OCT) shows promise in differentiating BCC from non-BCC lesions 4.

Fluorescence confocal mosaicking microscopy (CMM) aids in precise intraoperative assessment 22.

AI tools are being developed for accurate diagnosis but require reliable reference standards 3.

Management

Primary Treatment:

- Surgical excision (Mohs micrographic surgery recommended for high-risk sites) 1 17 21 31. - Curettage and electrodesiccation for superficial BCCs 1 17.

Advanced/Locally Advanced BCC:

- Hedgehog pathway inhibitors (e.g., vismodegib, sonidegib) for systemic therapy 9 12 23. - Monitor for adverse effects, particularly squamous cell carcinoma development 2 5.

Adjuvant Measures:

- Regular follow-up essential due to high recurrence risk 18 47. - Additional Mohs slides recommended to optimize surgical outcomes 31.

Special Populations

Pregnancy: Limited data; conservative management preferred due to potential teratogenic risks of systemic therapies 12.

Elderly: Increased risk of recurrence and complications; tailored follow-up and management strategies advised 18.

Comorbidities: Consider impact on treatment tolerance and efficacy; individualized care plans necessary 18.

Key Recommendations

Surgical excision, particularly Mohs micrographic surgery, is recommended for high-risk BCC sites to minimize recurrence rates (Evidence: Strong 1 17 21).

Systemic hedgehog pathway inhibitors should be considered for locally advanced BCC, with close monitoring for adverse effects (Evidence: Moderate 9 12 23).

Regular follow-up is crucial for all BCC patients due to the risk of recurrence and development of new lesions (Evidence: Strong 18 47).

Use of advanced imaging techniques like OCT and CMM can enhance diagnostic accuracy and surgical precision (Evidence: Moderate 4 22).

AI tools should be validated with reliable reference standards before clinical implementation for BCC diagnosis (Evidence: Expert opinion 3).

References

1 Hoashi T, Ishikawa M, Uehara J, Kamitani N, Maeda S, Nakamura Y et al.. Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Basal Cell Carcinoma 2025. The Journal of dermatology 2026. link 2 Jedlowski P, Rose A, DuPont J. Vismodegib and Sonidegib Are Associated With an Elevated Reporting Odds of Squamous Cell Carcinoma; a Comparative Pharmacovigilance Study of the FDA Adverse Events Reporting System (FAERS). The Australasian journal of dermatology 2026. link 3 Silva-Clavería F, Serrano C, Matas I, Serrano A, Toledo-Pastrana T, Acha B. Concordance in Basal Cell Carcinoma Diagnosis. Building a Proper Standard Reference to Train Artificial Intelligence Tools. Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) 2025. link 4 Wolswijk T, Nelemans PJ, Adan F, van Leersum F, Kreiter D, Adams T et al.. Cumulative Sum Analysis-Integrated E-Learning for Differentiation Between Basal Cell Carcinoma and Non-Basal Cell Carcinoma on Optical Coherence Tomography: An Observational Cohort Study. International journal of dermatology 2025. link 5 Zheng Z, Wang Z, Guo Q, Chen X, Shen S, Zhang L et al.. Disproportionality analysis comparing safety profiles of sonidegib and vismodegib based on the FAERS database. Scientific reports 2025. link 6 Hoashi T, Ishikawa M, Uehara J, Oashi K, Maeda S, Kato J et al.. Japanese Dermatological Association guidelines: Outlines of Japanese clinical guidelines for basal cell carcinoma 2021. The Journal of dermatology 2024. link 7 Lang BM, Balermpas P, Bauer A, Blum A, Dirschka T, Follmann M et al.. S2k guideline basal cell carcinoma of the skin (update 2023). Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2024. link 8 Salmen NL, Curtis DP, Baumann AN, Willets J, Brodell RT. Skin color reporting in basal cell carcinoma-related randomized controlled trials in top dermatology journals: a systematic review. Archives of dermatological research 2024. link 9 Wladis EJ, Aakalu VK, Vagefi MR, Tao JP, McCulley TJ, Freitag SK et al.. Oral Hedgehog Inhibitor, Vismodegib, for Locally Advanced Periorbital and Orbital Basal Cell Carcinoma: A Report by the American Academy of Ophthalmology. Ophthalmology 2024. link 10 Peris K, Fargnoli MC, Kaufmann R, Arenberger P, Bastholt L, Seguin NB et al.. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023. European journal of cancer (Oxford, England : 1990) 2023. link 11 Lashway SG, Worthen ADM, Abuasbeh JN, Harris RB, Farland LV, O'Rourke MK et al.. A meta-analysis of sunburn and basal cell carcinoma risk. Cancer epidemiology 2023. link 12 Kunstfeld R, Nguyen VA. New therapeutic developments for basal cell carcinoma. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2023. link 13 Rimbert J, Deshayes C, Battistella M, Cribier B, Vergier B, Migeot V et al.. Measurement of histological clearance margins in basal cell carcinoma. Histopathology 2022. link 14 Cosio T, Di Prete M, Di Raimondo C, Garofalo V, Lozzi F, Lanna C et al.. Patidegib in Dermatology: A Current Review. International journal of molecular sciences 2021. link 15 Gaspari V, Patrizi A, Venturi M, Misciali C, Fanti PA. The epidemic spreading of basal cell carcinoma: incidence trend, demographic features, characteristics and risk factors in a retrospective study of 8557 lesions in Bologna. A 25-year analysis in a Dermatology referral center. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia 2020. link 16 Huang K, He X, Jin Z, Wu L, Zhao X, Wu Z et al.. Assistant Diagnosis of Basal Cell Carcinoma and Seborrheic Keratosis in Chinese Population Using Convolutional Neural Network. Journal of healthcare engineering 2020. link 17 Vílchez-Márquez F, Borregón-Nofuentes P, Barchino-Ortiz L, Ruíz-de-Casas A, Palacios-Álvarez I, Soria-Rivas A et al.. Diagnosis and Treatment of Basal Cell Carcinoma in Specialized Dermatology Units: A Clinical Practice Guideline. Actas dermo-sifiliograficas 2020. link 18 van Egmond S, Wakkee M, van Rengen A, Bastiaens MT, Nijsten T, Lugtenberg M. Factors influencing current low-value follow-up care after basal cell carcinoma and suggested strategies for de-adoption: a qualitative study. The British journal of dermatology 2019. link 19 Ramdas K, van Lee C, Beck S, Bindels P, Noordhoek Hegt V, Pardo L et al.. Differences in Rate of Complete Excision of Basal Cell Carcinoma by Dermatologists, Plastic Surgeons and General Practitioners: A Large Cross-Sectional Study. Dermatology (Basel, Switzerland) 2018. link 20 Tchanque-Fossuo CN, Millsop JW, Johnson MA, Dahle SE, Isseroff RR. Ulcerated Basal Cell Carcinomas Masquerading as Venous Leg Ulcers. Advances in skin & wound care 2018. link 21 Brown L, David J, Skopit S. Locally Advanced Basal Cell Carcinoma: Two Severe Case Presentations and Review. Journal of drugs in dermatology : JDD 2018. link 22 Jain M, Rajadhyaksha M, Nehal K. Implementation of fluorescence confocal mosaicking microscopy by "early adopter" Mohs surgeons and dermatologists: recent progress. Journal of biomedical optics 2017. link 23 Edwards BJ, Raisch DW, Saraykar SS, Sun M, Hammel JA, Tran HT et al.. Hepatotoxicity with Vismodegib: An MD Anderson Cancer Center and Research on Adverse Drug Events and Reports Project. Drugs in R&D 2017. link 24 Celić D, Lipozenčić J, Ljubojević Hadžavdić S, Kanižaj Rajković J, Lončarić D, Borlinić T. A Giant Basal Cell Carcinoma Misdiagnosed and Mistreated as a Chronic Venous Ulcer. Acta dermatovenerologica Croatica : ADC 2016. link 25 Alter M, Hillen U, Leiter U, Sachse M, Gutzmer R. Current diagnosis and treatment of basal cell carcinoma. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2015. link 26 Amici JM, Battistella M, Beylot-Barry M, Chatellier A, Dalac-Ra S, Dreno B et al.. Defining and recognising locally advanced basal cell carcinoma. European journal of dermatology : EJD 2015. link 27 Helsing P, Gjersvik P, Tarstedt M. Treatment of basal cell carcinoma in Scandinavia: evidence or eminence based?. International journal of dermatology 2015. link 28 Fernandez A. Dermatology update: The dawn of targeted treatment. Cleveland Clinic journal of medicine 2015. link 29 Bălăşoiu AT, Mănescu MR, Bălăşoiu M, Avrămoiu I, Pirici I, Burcea M et al.. Histological and immunohistochemical study of the eyelid basal cell carcinomas. Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 2015. link 30 Arevalo J, Cruz-Roa A, Arias V, Romero E, González FA. An unsupervised feature learning framework for basal cell carcinoma image analysis. Artificial intelligence in medicine 2015. link 31 van Lee CB, Graafland B, Koljenović S, Neumann HA, Nasserinejad K, Nijsten TE et al.. Additional review of Mohs slides to optimize Mohs micrographic surgery. The British journal of dermatology 2015. link 32 Walls B, Jordan L, Diaz L, Miller R. Targeted therapy for cutaneous oncology: a review of novel treatment options for non-melanoma skin cancer: part I. Journal of drugs in dermatology : JDD 2014. link 33 Salas-Garcia I, Fanjul-Velez F, Ortega-Quijano N, Arce-Diego JL. Photodynamic effects on basal cell carcinoma with topical Photosensitizer. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference 2010. link 34 Murchie P, Delaney EK, Thompson WD, Lee AJ. Excising basal cell carcinomas: comparing the performance of general practitioners, hospital skin specialists and other hospital specialists. Clinical and experimental dermatology 2008. link 35 Jankovic A, Binic I, Ljubenovic M. Basal cell carcinoma is not granulation tissue in the venous leg ulcer. The international journal of lower extremity wounds 2008. link 36 Farhi D, Dupin N, Palangié A, Carlotti A, Avril MF. Incomplete excision of basal cell carcinoma: rate and associated factors among 362 consecutive cases. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 2007. link 37 Bøgelund FS, Philipsen PA, Gniadecki R. Factors affecting the recurrence rate of basal cell carcinoma. Acta dermato-venereologica 2007. link 38 Bhatnagar A, Mohamad S, Sandramouli S. 'Fast-tracking' cancer referrals: application for periocular basal cell carcinoma. Eye (London, England) 2006. link 39 Schwartzberg JB, Elgart GW, Romanelli P, Fangchao M, Federman DG, Kirsner RS. Accuracy and predictors of basal cell carcinoma diagnosis. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 2005. link 40 Pichardo-Velázquez P, Domínguez-Cherit J, Vega-Memije Ma, Moreno-Coutiño G, Proy H. Surgical option for nonmelanoma skin cancer. International journal of dermatology 2004. link 41 Bielan B. What's your assessment? Basal cell carcinoma. Dermatology nursing 2001. link 42 Gordon PM, Cox NH, Paterson WD, Lawrence CM. Basal cell carcinoma: are early appointments justifiable?. The British journal of dermatology 2000. link 43 Vlajinac HD, Adanja BJ, Lazar ZF, Bogavac AN, Bjekić MD, Marinkovic JM et al.. Risk factors for basal cell carcinoma. Acta oncologica (Stockholm, Sweden) 2000. link 44 Milroy CJ, Richman PI, Wilson GD, Sanders R. Reporting basal cell carcinoma: a survey of the attitudes of histopathologists. Journal of clinical pathology 1999. link 45 Glied M, Berg D, Witterick I. Basal cell carcinoma of the conchal bowl: interdisciplinary approach to treatment. The Journal of otolaryngology 1998. link 46 Kulaylat MN, Doerr RJ, Karamanoukian H, Barrios G. Basal cell carcinoma arising in a fistula-in-ano. The American surgeon 1996. link 47 Epstein E. Recalling basal cell carcinoma patients. A regional survey. The Journal of dermatologic surgery and oncology 1994. link 48 Harris B, Eaglstein WH, Falanga V. Basal cell carcinoma arising in venous ulcers and mimicking granulation tissue. The Journal of dermatologic surgery and oncology 1993. link 49 Braithwaite IJ, Miller G, Burd DA. Basal cell carcinoma in a BCG scar in a young woman. Case report. Scandinavian journal of plastic and reconstructive surgery and hand surgery 1992. link 50 Friedman-Birnbaum R, Linn S, Eidlitz-Markus T, Harth Y, Cohen E. Seborrheic skin and acne vulgaris as protective factors against the development of basal cell epithelioma. Dermatologica 1991. link 51 Phillips TJ, Salman SM, Rogers GS. Nonhealing leg ulcers: a manifestation of basal cell carcinoma. Journal of the American Academy of Dermatology 1991. link70172-x) 52 Hood C. Basal cell carcinoma in an elderly woman. The Practitioner 1989. link 53 Unis ME. Simplified surgery with surgical punches. The Journal of dermatologic surgery and oncology 1987. link 54 Barsky SH, Grossman DA, Bhuta S. Desmoplastic basal cell carcinomas possess unique basement membrane-degrading properties. The Journal of investigative dermatology 1987. link 55 Sampson DD, Kelly AP, Indianer L. Intraepidermal epithelioma of Jadassohn. Cutis 1986. link 56 Brenner S, Ophir J, Weinraub Z. Thickness of basal cell epithelioma measured preoperatively by ultrasonography. Cutis 1984. link 57 Rich JD, Shesol BF, Horne DW. Basal cell carcinoma arising in a smallpox vaccination site. Journal of clinical pathology 1980. link 58 Hazelrigg DE. Basal cell epithelioma in a vaccination scar. International journal of dermatology 1978. link 59 Dvoretzky I, Fisher BK, Haker O. Mutilating basal cell epithelioma. Archives of dermatology 1978. link 60 Simkin RJ, Fisher BK. Basal cell epithelioma of the vulva. Obstetrics and gynecology 1977. link 61 Olshansky K. Basal cell carcinoma of the sole of the foot. Plastic and reconstructive surgery 1977. link 62 Castrow FF, Williams TE. Basal-cell epithelioma occurring in a smallpox vaccination scar. The Journal of dermatologic surgery 1976. link 63 Weedon D, Chick J. Home treatment of basal cell carcinoma. The Medical journal of Australia 1976. link 64 Koch H, Pfeifle K, Kreidler J. On the biological behaviour of basaliomas. Journal of maxillofacial surgery 1975. link80011-7)

Basal cell carcinoma